Eastern European Region
The total estimated cost of country activities in the Eastern European Region from 2006 to 2015 is US$9.1 billion. As multidrug-resistant TB is an issue in the region, the cost of DOTS-Plus implementation is much bigger in this region compared to the other regions.
The estimated total funding gap is US$4.2 billion - the second largest in the regions.
About 2.2 million people will be treated in DOTS programmes from 2006 to 2015, and more than 410 000 in DOTS-Plus programmes. In addition, about 31 000 TB patients will be enrolled on antiretroviral therapy.
The combined effect of all interventions will be to prevent about 218 000 deaths, in comparison with a situation in which no DOTS programmes are implemented.
The Global Plan in the Eastern European Region
Total cost: US $9.1 billion
Country activities:
- DOTS Expansion
- DOTS-Plus
- TB/HIV
- ACSM
Patients treated: 2.2 million
Lives saved: 0.2 million
Available funding: US$4.8 billion
Total funding gap: US$4.2 billion
Documents
Estimated costs and impacts of planned intensified activities 2006-2015 [.pdf]
Intensified action to control TB in Europe [.pdf]
Although full implementation of the Global Plan is expected to result in considerable progress over the ten years, the targets of halving TB prevalence and death may not be achieved by 2015 in Eastern Europe.
